Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 235 articles:
HTML format



Single Articles


    July 2022
  1. WU X, Cheng L, Liu X, Sun Y, et al
    Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.
    Ann Hematol. 2022;101:1493-1498.
    PubMed     Abstract available


  2. HIRANO M, Tamba M, Inoue N, Ikegami M, et al
    Durable response of therapy-related MDS/AML with concomitant Waldenstrom's macroglobulinemia treated with venetoclax and azacitidine.
    Ann Hematol. 2022;101:1587-1589.
    PubMed    


    June 2022
  3. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Ann Hematol. 2022 Jun 24. pii: 10.1007/s00277-022-04895.
    PubMed     Abstract available


  4. WOLACH O, Frisch A, Shargian L, Yeshurun M, et al
    Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
    Ann Hematol. 2022 Jun 23. pii: 10.1007/s00277-022-04883.
    PubMed     Abstract available


  5. KATHPALIA M, Mishra P, Bajpai R, Bhurani D, et al
    Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2022 Jun 21. pii: 10.1007/s00277-022-04880.
    PubMed     Abstract available


  6. YANG X, Zhang R, Zhang Z
    The rare IRF2BP2-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2022 Jun 15. pii: 10.1007/s00277-022-04874.
    PubMed    


  7. BRAITSCH K, Schwarz A, Koch K, Hubbuch M, et al
    Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Ann Hematol. 2022;101:1311-1319.
    PubMed     Abstract available


  8. WATTEBLED KJ, Drumez E, Coiteux V, Magro L, et al
    Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2022;101:1321-1331.
    PubMed     Abstract available


  9. LEUNG WY, Cheuk DK, Cheng FW, Leung AW, et al
    Outcome prediction of chronic myeloid leukemia (CML) in children.
    Ann Hematol. 2022 Jun 1. pii: 10.1007/s00277-022-04852.
    PubMed     Abstract available


    May 2022
  10. OCHS MA, Marini BL, Perissinotti AJ, Foucar CE, et al
    Oncology stewardship in acute myeloid leukemia.
    Ann Hematol. 2022 May 26. pii: 10.1007/s00277-022-04872.
    PubMed     Abstract available


  11. SAITO K, Ichikawa S, Ohtomo R, Hatta S, et al
    Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia.
    Ann Hematol. 2022 May 25. pii: 10.1007/s00277-022-04875.
    PubMed    


  12. KOSCHADE SE, Stratmann JA, Finkelmeier F, Wagner S, et al
    Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.
    Ann Hematol. 2022 May 20. pii: 10.1007/s00277-022-04862.
    PubMed     Abstract available


  13. ZENG Q, Xiang B, Liu Z
    Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
    Ann Hematol. 2022 May 16. pii: 10.1007/s00277-022-04863.
    PubMed     Abstract available


  14. PODVIN B, Guermouche H, Roynard P, Goursaud L, et al
    Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia.
    Ann Hematol. 2022 May 13. pii: 10.1007/s00277-022-04861.
    PubMed    


  15. SHARMA R, Jani C
    Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030.
    Ann Hematol. 2022 May 10. pii: 10.1007/s00277-022-04843.
    PubMed     Abstract available


  16. BOQUOI A, Banahan SM, Mohring A, Savickaite I, et al
    Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.
    Ann Hematol. 2022;101:1031-1038.
    PubMed     Abstract available


  17. HOFER KD, Schanz U, Schwotzer R, Nair G, et al
    Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years.
    Ann Hematol. 2022;101:1097-1106.
    PubMed     Abstract available


  18. WANG Y, Hou W, Li H, Tian X, et al
    Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
    Ann Hematol. 2022;101:1039-1047.
    PubMed     Abstract available


  19. SATO M, Yasunaga M, Ohzu M, Toyama K, et al
    Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report.
    Ann Hematol. 2022;101:1153-1155.
    PubMed    


  20. HAZENBERG CLE, Diepstra A, Santing M, Huls GA, et al
    Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
    Ann Hematol. 2022;101:1133-1134.
    PubMed    


  21. SHALLIS RM, Pucar D, Perincheri S, Gore SD, et al
    Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.
    Ann Hematol. 2022;101:1145-1147.
    PubMed    


    April 2022
  22. SEKERES MA, Schuster M, Joris M, Krauter J, et al
    A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Apr 30. pii: 10.1007/s00277-022-04853.
    PubMed     Abstract available


  23. LI Y, Tang T, Xiao J, Li B, et al
    Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.
    Ann Hematol. 2022 Apr 20. pii: 10.1007/s00277-022-04840.
    PubMed     Abstract available


  24. WANG Y, Wang T, Yu Y, Wang Q, et al
    Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
    Ann Hematol. 2022 Apr 18. pii: 10.1007/s00277-022-04795.
    PubMed     Abstract available


  25. LAUW MIS, Hakim N, Arora S, Prakash S, et al
    A case of plasma cell neoplasm-associated chronic neutrophilic leukemia with ASXL1 and JAK2V617F mutations.
    Ann Hematol. 2022 Apr 14. pii: 10.1007/s00277-022-04834.
    PubMed    


  26. GREINER SM, Marklin M, Holzmayer S, Kaban K, et al
    Identification of CD105 (endoglin) as novel risk marker in CLL.
    Ann Hematol. 2022;101:773-780.
    PubMed     Abstract available


    March 2022
  27. MORIMOTO S, Kondo T, Taya T, Matsuo H, et al
    Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04825.
    PubMed    


  28. LI Y, Dai H, Yao D, Gao X, et al
    Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04823.
    PubMed    


  29. TSUSHIMA T, Sato N, Guo YM, Uchiyama S, et al
    Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04796.
    PubMed    


  30. CHAUHAN P, Gupta A, Gopinathan M, Sanjeev, et al
    Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04814.
    PubMed     Abstract available


  31. UMINSKI K, Khalife R, Kekre N, Tinmouth A, et al
    Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 21. pii: 10.1007/s00277-022-04819.
    PubMed    


  32. CAETANO DOS SANTOS FL, Michalek IM, Wojciechowska U, Didkowska J, et al
    Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999-2020.
    Ann Hematol. 2022 Mar 15. pii: 10.1007/s00277-022-04758.
    PubMed     Abstract available


  33. BI X, French Z, Palmisiano N, Wen KY, et al
    The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions.
    Ann Hematol. 2022 Mar 14. pii: 10.1007/s00277-022-04812.
    PubMed     Abstract available


  34. ROBIN JB, Theron A, Quittet P, Exbrayat C, et al
    Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
    Ann Hematol. 2022 Mar 12. pii: 10.1007/s00277-022-04779.
    PubMed     Abstract available


  35. ROSETTI M, De la Salle B, Farneti G, Clementoni A, et al
    The added value of digital morphological analysis in the evaluation of peripheral blood films: the report of an UKNEQAS external quality assessment sample.
    Ann Hematol. 2022;101:729-730.
    PubMed    


    February 2022
  36. HERMEL DJ, Cheng B, Bhangoo MS, Burian C, et al
    Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
    Ann Hematol. 2022 Feb 26. pii: 10.1007/s00277-022-04800.
    PubMed     Abstract available


  37. BAYSAL M, Gursoy V, Hunutlu FC, Erkan B, et al
    The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04798.
    PubMed     Abstract available


  38. ROBAK E, Jesionek-Kupnicka D, Stelmach P, Kupnicki P, et al
    Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04753.
    PubMed    


  39. TANG G, Zou Y, Wang SA, Borthakur G, et al
    3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.
    Ann Hematol. 2022 Feb 20. pii: 10.1007/s00277-022-04767.
    PubMed     Abstract available


  40. FU W, Huang A, Tang G, Yang J, et al
    A case report of BCR-ABL1 rearrangement in de novo adult T-cell lymphoblastic leukemia/lymphoma with normal karyotype.
    Ann Hematol. 2022 Feb 14. pii: 10.1007/s00277-022-04791.
    PubMed    


  41. MARTELLA F, Cerrano M, Di Cuonzo D, Secreto C, et al
    Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.
    Ann Hematol. 2022 Feb 7. pii: 10.1007/s00277-022-04770.
    PubMed     Abstract available


  42. KEREN-FROIM N, Heering G, Sharvit G, Zlotnik M, et al
    ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
    Ann Hematol. 2022;101:309-316.
    PubMed     Abstract available


  43. SCHMITZ-FEUERHAKE I, Frentzel-Beyme R, Wolff R
    Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature.
    Ann Hematol. 2022;101:243-250.
    PubMed     Abstract available


  44. DI GIACOMO D, Quintini M, Pierini V, Pellanera F, et al
    Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
    Ann Hematol. 2022;101:297-307.
    PubMed     Abstract available


  45. DUNN WG, Gu MS, Fabre MA, Cooper J, et al
    The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients.
    Ann Hematol. 2022;101:443-445.
    PubMed    


    January 2022
  46. BAEK J, Kim MK, Gu MJ
    Myelolipoma/extramedullary hematopoiesis within adrenal cortical adenoma increased in size during chronic myelogenous leukemia treatment.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04768.
    PubMed    


  47. FREDMAN D, Moshe Y, Wolach O, Heering G, et al
    Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-021-04738.
    PubMed     Abstract available


  48. QIU L, Nunez CA, Tang G, Cuglievan B, et al
    A rare case of acute megakaryoblastic leukemia with t(11;17)(q23;q21) and KMT2A::MLLT6 fusion.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04769.
    PubMed    


  49. MELLADO-GAZQUEZ A, Gomez-Nunez MR, Jurado-Herrera S, Prats-Martin C, et al
    Multiple erythrophagocytosis by erythroid blasts in acute myeloid leukemia with BCR-ABL1.
    Ann Hematol. 2022 Jan 27. pii: 10.1007/s00277-021-04742.
    PubMed    


  50. DUTTA S, Moritz J, Pregartner G, Thallinger GG, et al
    Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Ann Hematol. 2022 Jan 26. pii: 10.1007/s00277-022-04766.
    PubMed     Abstract available


  51. MAO YY, Cai HC, Shen KN, Chang L, et al
    Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study.
    Ann Hematol. 2022 Jan 17. pii: 10.1007/s00277-022-04764.
    PubMed     Abstract available


  52. ONISHI A, Fuji S, Kitano S, Maeshima AM, et al
    Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
    Ann Hematol. 2022 Jan 15. pii: 10.1007/s00277-022-04760.
    PubMed     Abstract available


  53. TISO F, Koorenhof-Scheele TN, Huys E, Martens JHA, et al
    Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.
    Ann Hematol. 2022 Jan 13. pii: 10.1007/s00277-021-04747.
    PubMed     Abstract available


  54. HARADA K, Mizuno S, Yano S, Takami A, et al
    Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.
    Ann Hematol. 2022 Jan 6. pii: 10.1007/s00277-021-04731.
    PubMed     Abstract available


  55. ZEIDAN AM, DeAngelo DJ, Palmer J, Seet CS, et al
    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Jan 4. pii: 10.1007/s00277-021-04734.
    PubMed     Abstract available


  56. KONUMA T, Ooi J, Nagayama H, Tomonari A, et al
    Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.
    Ann Hematol. 2022;101:177-189.
    PubMed     Abstract available


  57. GUPTA A, Desai N, Sanjeev, Chauhan P, et al
    Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India.
    Ann Hematol. 2022;101:69-79.
    PubMed     Abstract available


  58. SAKURAI M, Nannya Y, Yamazaki R, Yamaguchi K, et al
    Germline RUNX1 translocation in familial platelet disorder with propensity to myeloid malignancies.
    Ann Hematol. 2022;101:237-239.
    PubMed    


    December 2021
  59. DALELA D, Bledsoe JR, Patel SA
    Clonal IgH gene rearrangements identify Richter's transformation to diffuse large B cell lymphoma.
    Ann Hematol. 2021;100:3075-3077.
    PubMed    


  60. PULIDO-PEREZ A, Bergon-Sendin M, Mateos-Mayo A, Parra-Blanco V, et al
    Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
    Ann Hematol. 2021;100:3065-3066.
    PubMed    


    November 2021
  61. ARCANI R, Colle J, Cauchois R, Koubi M, et al
    Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
    Ann Hematol. 2021;100:2799-2803.
    PubMed     Abstract available


  62. REINERT J, Beitzen-Heineke A, Wethmar K, Stelljes M, et al
    Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.
    Ann Hematol. 2021;100:2727-2732.
    PubMed     Abstract available


  63. MAYER MC, Berg JL, Perfler B, Hatzl S, et al
    miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
    Ann Hematol. 2021;100:2845-2847.
    PubMed    


    October 2021
  64. STANGANELLI C, Torres DC, Ortega C, Marquez ME, et al
    Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.
    Ann Hematol. 2021 Oct 28. pii: 10.1007/s00277-021-04703.
    PubMed     Abstract available


  65. MENDES FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, et al
    Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting.
    Ann Hematol. 2021 Oct 21. pii: 10.1007/s00277-021-04687.
    PubMed     Abstract available


  66. ZHANG Y, Qian JJ, Shen YJ, Hang SJ, et al
    The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 18. pii: 10.1007/s00277-021-04699.
    PubMed    


  67. HOU HA, Tzeng HE, Liu HY, Chou WC, et al
    Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
    Ann Hematol. 2021 Oct 13. pii: 10.1007/s00277-021-04670.
    PubMed     Abstract available


  68. PASVOLSKY O, Shimony S, Ram R, Shimoni A, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Ann Hematol. 2021 Oct 9. pii: 10.1007/s00277-021-04693.
    PubMed     Abstract available


  69. UMINSKI K, Khalife R, Fulcher J, Duffett L, et al
    Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 6. pii: 10.1007/s00277-021-04688.
    PubMed    


  70. CHOI HS, Hong J, Hwang SM, Lee JH, et al
    Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Ann Hematol. 2021;100:2567-2574.
    PubMed     Abstract available


  71. SHAH N, Rakszawski K, Nickolich M, Ehmann C, et al
    Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
    Ann Hematol. 2021;100:2585-2592.
    PubMed     Abstract available


  72. BALLO O, Eladly F, Koschade S, Buttner S, et al
    Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy.
    Ann Hematol. 2021;100:2603-2611.
    PubMed     Abstract available


  73. DAS N, Gupta R, Gupta SK, Bakhshi S, et al
    Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
    Ann Hematol. 2021;100:2487-2500.
    PubMed     Abstract available


  74. SAVASAN S, Buck S, Gadgeel M, Poulik J, et al
    Persistent pseudo-Pelger-Huet anomaly.
    Ann Hematol. 2021;100:2661-2663.
    PubMed    


  75. MARRA A, Martino G, Scarpelli N, Perriello V, et al
    Collision diffuse large B cell lymphoma and myeloid sarcoma in the liver.
    Ann Hematol. 2021;100:2649-2651.
    PubMed    


    September 2021
  76. KIM TH, Choi YW, Ahn MS, Choi YS, et al
    Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia.
    Ann Hematol. 2021 Sep 30. pii: 10.1007/s00277-021-04673.
    PubMed     Abstract available


  77. ZHAO P, Ni M, Ma D, Fang Q, et al
    Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Sep 27. pii: 10.1007/s00277-021-04674.
    PubMed     Abstract available


  78. FAGUNDES EM, Neto NN, Caldas LM, Aragao JR, et al
    Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil.
    Ann Hematol. 2021 Sep 17. pii: 10.1007/s00277-021-04659.
    PubMed    


  79. XU RZ, Karsan A, Xu Z, Berry BR, et al
    A rare de novo pure erythroid leukemia with JAK2 R683S mutation.
    Ann Hematol. 2021 Sep 4. pii: 10.1007/s00277-021-04657.
    PubMed    


  80. YANADA M, Konuma T, Yamasaki S, Mizuno S, et al
    The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04661.
    PubMed     Abstract available


  81. FUJI S, Kida S, Nakata K, Morishima T, et al
    Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04631.
    PubMed     Abstract available


  82. HEINICKE T, Krahl R, Kahl C, Cross M, et al
    Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
    Ann Hematol. 2021;100:2387-2398.
    PubMed     Abstract available


  83. QI J, Zhang R, Cai C, Wang H, et al
    HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.
    Ann Hematol. 2021;100:2351-2361.
    PubMed     Abstract available


  84. CHEN X, Liu C, Zhang A, Wu W, et al
    Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Ann Hematol. 2021;100:2269-2277.
    PubMed     Abstract available


  85. SIM JPY, Lie AKW, Ng MY, Kwong YL, et al
    Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab.
    Ann Hematol. 2021;100:2399-2402.
    PubMed    


    August 2021
  86. GUERY R, Suarez F, Lanternier F, Bougnoux ME, et al
    Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
    Ann Hematol. 2021 Aug 13. pii: 10.1007/s00277-021-04622.
    PubMed     Abstract available


  87. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
    Ann Hematol. 2021 Aug 6. pii: 10.1007/s00277-021-04607.
    PubMed     Abstract available


  88. MIAN AA, Haberbosch I, Khamaisie H, Agbarya A, et al
    Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K).
    Ann Hematol. 2021;100:2023-2029.
    PubMed     Abstract available


  89. WELLBROCK J, Behrmann L, Muschhammer J, Modemann F, et al
    The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia.
    Ann Hematol. 2021 Aug 1. pii: 10.1007/s00277-021-04602.
    PubMed     Abstract available


    July 2021
  90. MI R, Chen L, Yang H, Zhang Y, et al
    Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia.
    Ann Hematol. 2021 Jul 27. pii: 10.1007/s00277-021-04621.
    PubMed     Abstract available


  91. MATSUDA K, Jo T, Toyama K, Nakazaki K, et al
    Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
    Ann Hematol. 2021 Jul 26. pii: 10.1007/s00277-021-04620.
    PubMed     Abstract available


  92. ALRAWASHDH N, Sweasy J, Erstad B, McBride A, et al
    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04600.
    PubMed     Abstract available


  93. ELNAIR R, Ellithi M, Kallam A, Shostrom V, et al
    Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04603.
    PubMed     Abstract available


  94. KONG J, Qin YZ, Zhao XS, Hou Y, et al
    Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04606.
    PubMed     Abstract available


  95. MICHAELIS S, Pichler A, Stelzer I, Schoffmann L, et al
    Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.
    Ann Hematol. 2021 Jul 16. pii: 10.1007/s00277-021-04585.
    PubMed    


  96. HARA R, Onizuka M, Kikkawa E, Shiraiwa S, et al
    Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2021 Jul 11. pii: 10.1007/s00277-021-04587.
    PubMed     Abstract available


  97. BARZEGAR M, Farsani MA, Rafiee M, Amiri V, et al
    Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARalpha transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04579.
    PubMed     Abstract available


  98. TANIGAWA T, Sakurai M, Kato J, Mizuno K, et al
    Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04586.
    PubMed    


  99. GREIL R, Tedeschi A, Moreno C, Anz B, et al
    Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Ann Hematol. 2021;100:1733-1742.
    PubMed     Abstract available


  100. GADGEEL M, AlQanber B, Buck S, Taub JW, et al
    Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
    Ann Hematol. 2021;100:1695-1700.
    PubMed     Abstract available


    June 2021
  101. VIRK H, Rana S, Sharma P, Bose PL, et al
    Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Ann Hematol. 2021 Jun 22. pii: 10.1007/s00277-021-04574.
    PubMed     Abstract available


  102. WYSOCKA-SLOWIK A, Gil L, Slebioda Z, Kregielczak A, et al
    Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation.
    Ann Hematol. 2021 Jun 12. pii: 10.1007/s00277-021-04568.
    PubMed     Abstract available


  103. KRECAK I, Cengic M, Skoric I, Nakic M, et al
    Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jun 10. pii: 10.1007/s00277-021-04570.
    PubMed    


  104. DOU X, Zheng F, Zhang L, Jin J, et al
    Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
    Ann Hematol. 2021 Jun 5. pii: 10.1007/s00277-021-04544.
    PubMed     Abstract available


  105. AL-SARAYFI D, Meeuwes FO, Munnink TO, Plattel W, et al
    Successful treatment of hairy cell leukemia variant with obinutuzumab.
    Ann Hematol. 2021 Jun 4. pii: 10.1007/s00277-021-04559.
    PubMed    


  106. LARIBI K, Sobh M, Ghez D, Baugier de Materre A, et al
    Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
    Ann Hematol. 2021;100:1359-1376.
    PubMed     Abstract available


  107. ZENG Z, Ly C, Daver N, Cortes J, et al
    High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
    Ann Hematol. 2021;100:1485-1496.
    PubMed     Abstract available


    May 2021
  108. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 May 12. pii: 10.1007/s00277-021-04545.
    PubMed    


  109. KONG J, Chen N, Li M, Zhang J, et al
    Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2021 May 6. pii: 10.1007/s00277-021-04530.
    PubMed    


  110. DEVOS T, Havelange V, Theunissen K, Meers S, et al
    Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Ann Hematol. 2021 May 4. pii: 10.1007/s00277-021-04507.
    PubMed     Abstract available


  111. GONZALEZ JS, Perusini MA, Basquiera AL, Alfonso G, et al
    Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
    Ann Hematol. 2021 May 1. pii: 10.1007/s00277-021-04539.
    PubMed     Abstract available


  112. SALAMONOWICZ-BODZIOCH M, Fraczkiewicz J, Czyzewski K, Zajac-Spychala O, et al
    Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.
    Ann Hematol. 2021;100:1283-1293.
    PubMed     Abstract available


  113. TANG KHK, Ip AHW, Kwong YL
    Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia.
    Ann Hematol. 2021;100:1337-1339.
    PubMed    


  114. HORIUCHI M, Yoshida M, Yamasaki K, Sakagami R, et al
    Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
    Ann Hematol. 2021;100:1329-1331.
    PubMed    


  115. BERNARDI S, Zanaglio C, Farina M, Polverelli N, et al
    dsDNA from extracellular vesicles (EVs) in adult AML.
    Ann Hematol. 2021;100:1355-1356.
    PubMed    


    April 2021
  116. MARTINEZ SANCHEZ MP, Megias-Vericat JE, Rodriguez-Veiga R, Vives S, et al
    A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Ann Hematol. 2021 Apr 29. pii: 10.1007/s00277-021-04542.
    PubMed     Abstract available


  117. ZHAO H, Sun J, Yan L, Jin B, et al
    Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Ann Hematol. 2021 Apr 24. pii: 10.1007/s00277-021-04533.
    PubMed     Abstract available


  118. KE P, Zhang X, Liu S, Zhu Q, et al
    The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ann Hematol. 2021 Apr 22. pii: 10.1007/s00277-021-04528.
    PubMed     Abstract available


  119. ONAKA T, Kato-Ogura A, Otsuka Y, Iwai F, et al
    A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
    Ann Hematol. 2021 Apr 12. pii: 10.1007/s00277-021-04516.
    PubMed    


  120. OWATTANAPANICH W, Herzig J, Jahn N, Panina E, et al
    Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Ann Hematol. 2021 Apr 10. pii: 10.1007/s00277-021-04513.
    PubMed     Abstract available


  121. QIAN Y, Chen Y, Li X
    CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Ann Hematol. 2021 Apr 6. pii: 10.1007/s00277-021-04491.
    PubMed     Abstract available


  122. MODI D, Singh V, Kim S, Ayash L, et al
    Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Ann Hematol. 2021;100:969-978.
    PubMed     Abstract available


  123. HU L, Charwudzi A, Li Q, Zhu W, et al
    Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.
    Ann Hematol. 2021;100:1003-1012.
    PubMed     Abstract available


  124. SCHULER E, Wagner-Drouet EM, Ajib S, Bug G, et al
    Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2021;100:959-968.
    PubMed     Abstract available


  125. RETTIG AR, Ihorst G, Bertz H, Lubbert M, et al
    Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.
    Ann Hematol. 2021 Apr 1. pii: 10.1007/s00277-021-04494.
    PubMed     Abstract available


    March 2021
  126. LEOTTA S, Markovic U, Pirosa MC, Stella S, et al
    The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
    Ann Hematol. 2021 Mar 28. pii: 10.1007/s00277-021-04504.
    PubMed     Abstract available


  127. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 Mar 19. pii: 10.1007/s00277-021-04465.
    PubMed     Abstract available


  128. SHOUMARIYEH K, Jung J, Rassner M, Dold SM, et al
    Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Ann Hematol. 2021 Mar 13. pii: 10.1007/s00277-021-04490.
    PubMed    


  129. LIU J, Zhang XH, Xu LP, Wang Y, et al
    Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Mar 13. pii: 10.1007/s00277-021-04488.
    PubMed     Abstract available


  130. BALLO O, Eladly F, Buttner S, Stratmann JA, et al
    Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy.
    Ann Hematol. 2021 Mar 11. pii: 10.1007/s00277-021-04482.
    PubMed     Abstract available


  131. SCALZULLI E, Caocci G, Efficace F, Rizzo L, et al
    Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
    Ann Hematol. 2021 Mar 7. pii: 10.1007/s00277-021-04477.
    PubMed     Abstract available


  132. LI T, Chen H, Zhang Y, Zeng Y, et al
    Very rare lineage switch from acute myeloid leukemia with BCR-ABL1 to B-lymphoblastic leukemia.
    Ann Hematol. 2021 Mar 5. pii: 10.1007/s00277-021-04483.
    PubMed    


  133. ZUCENKA A, Maneikis K, Pugaciute B, Ringeleviciute U, et al
    Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
    Ann Hematol. 2021 Mar 4. pii: 10.1007/s00277-021-04471.
    PubMed     Abstract available


  134. BRUNE MM, Stussi G, Lundberg P, Vela V, et al
    Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
    Ann Hematol. 2021 Mar 2. pii: 10.1007/s00277-021-04467.
    PubMed     Abstract available


  135. STEINER N, Brunelli L, Hetzenauer G, Lindner B, et al
    Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience.
    Ann Hematol. 2021;100:809-816.
    PubMed     Abstract available


  136. YU WJ, Sun YQ, Han TT, Ye PP, et al
    Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study.
    Ann Hematol. 2021;100:799-808.
    PubMed     Abstract available


  137. BOSCH F, Navarro B, Crespo M, Alcoceba M, et al
    Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.
    Ann Hematol. 2021;100:825-830.
    PubMed     Abstract available


  138. LAHLIMI FZ, Tazi I
    A rare cause of respiratory failure in acute myeloid leukaemia patient.
    Ann Hematol. 2021;100:831-832.
    PubMed    


    February 2021
  139. ISOBE M, Konuma T, Masuko M, Uchida N, et al
    Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
    Ann Hematol. 2021 Feb 23. pii: 10.1007/s00277-021-04464.
    PubMed     Abstract available


  140. OLIVA S, De Paoli L, Ruggeri M, Caltagirone S, et al
    A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
    Ann Hematol. 2021;100:437-443.
    PubMed     Abstract available


  141. WANG Z, Liu W, Wang M, Li Y, et al
    Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
    Ann Hematol. 2021;100:465-479.
    PubMed     Abstract available


  142. GHOSH S, Chakraborty M, Samanta S, Sinha N, et al
    Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
    Ann Hematol. 2021;100:395-403.
    PubMed     Abstract available


  143. ENGEL NW, Reinert J, Borchert NM, Panagiota V, et al
    Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow.
    Ann Hematol. 2021;100:499-503.
    PubMed     Abstract available


  144. AKIMOTO M, Sakurai A, Nishiyama-Fujita Y, Ito C, et al
    The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
    Ann Hematol. 2021 Feb 1. pii: 10.1007/s00277-021-04440.
    PubMed     Abstract available


    January 2021
  145. BOUCLET F, Calleja A, Dilhuydy MS, Veronese L, et al
    Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
    Ann Hematol. 2021 Jan 25. pii: 10.1007/s00277-021-04419.
    PubMed     Abstract available


  146. DUAN W, Liu X, Zhao X, Jia J, et al
    Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
    Ann Hematol. 2021 Jan 20. pii: 10.1007/s00277-021-04432.
    PubMed     Abstract available


  147. TONG J, Zhang L, Liu H, Xu X, et al
    Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival.
    Ann Hematol. 2021 Jan 20. pii: 10.1007/s00277-021-04413.
    PubMed     Abstract available


  148. VOIGT M, Sinn K, Malouhi A, Gecks T, et al
    HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient.
    Ann Hematol. 2021 Jan 14. pii: 10.1007/s00277-021-04409.
    PubMed    


  149. AMIT O, On YB, Perez G, Shargian-Alon L, et al
    Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
    Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-021-04398.
    PubMed     Abstract available


  150. LIAO PW, Wang RC, Chen TC, Teng CJ, et al
    Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
    Ann Hematol. 2021 Jan 13. pii: 10.1007/s00277-020-04372.
    PubMed    


  151. SCHLAWECK S, Brossart P, Heine A
    Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient.
    Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04403.
    PubMed    


  152. KERUAKOUS AR, Balakrishna P, Schmidt SA, Autry MT, et al
    Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant.
    Ann Hematol. 2021 Jan 12. pii: 10.1007/s00277-021-04408.
    PubMed    


  153. MARTIN-MORO F, Garcia-Cosio M, Marquet-Palomanes J, Lopez-Gutierrez M, et al
    Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jan 9. pii: 10.1007/s00277-021-04393.
    PubMed    


  154. BRECCIA M, Celant S, Olimpieri PP, Olimpieri OM, et al
    Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
    Ann Hematol. 2021 Jan 7. pii: 10.1007/s00277-021-04406.
    PubMed     Abstract available


  155. MA YR, Xu LP, Zhang XH, Liu KY, et al
    Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings.
    Ann Hematol. 2021 Jan 7. pii: 10.1007/s00277-020-04359.
    PubMed     Abstract available


  156. CAOCCI G, Mulas O, Capodanno I, Bonifacio M, et al
    Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
    Ann Hematol. 2021 Jan 3. pii: 10.1007/s00277-020-04392.
    PubMed     Abstract available


  157. CHEN Q, Zhu XL, Zhao X, Liu X, et al
    Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2021 Jan 2. pii: 10.1007/s00277-020-04380.
    PubMed     Abstract available


  158. LIU J, Shen L, Huang H, Gao X, et al
    A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient.
    Ann Hematol. 2021;100:295-296.
    PubMed    


    December 2020
  159. ANGENENDT L, Hilgefort I, Mikesch JH, Schluter B, et al
    Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2020 Dec 19. pii: 10.1007/s00277-020-04382.
    PubMed     Abstract available


  160. YAMASAKI S, Mori J, Kanda J, Imahashi N, et al
    Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT.
    Ann Hematol. 2020;99:2927-2937.
    PubMed     Abstract available


  161. CHEN H, Qin Y, Yang J, Liu P, et al
    Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
    Ann Hematol. 2020;99:2847-2857.
    PubMed     Abstract available


    November 2020
  162. FUJI S, Kida S, Nakata K, Morishima T, et al
    Correction to: Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Regist
    Ann Hematol. 2020 Nov 28. pii: 10.1007/s00277-020-04352.
    PubMed     Abstract available


  163. LU Y, Zhao YL, Zhang JP, Xiong M, et al
    Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a s
    Ann Hematol. 2020 Nov 24. pii: 10.1007/s00277-020-04355.
    PubMed     Abstract available


  164. RASEKH EO, Osman R, Ibraheem D, Madney Y, et al
    Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
    Ann Hematol. 2020 Nov 23. pii: 10.1007/s00277-020-04354.
    PubMed     Abstract available


  165. WANG YH, Lin CC, Hsu CL, Hung SY, et al
    Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125.
    Ann Hematol. 2020 Nov 23. pii: 10.1007/s00277-020-04358.
    PubMed     Abstract available


  166. ROBAK E, Jesionek-Kupnicka D, Robak T
    Skin changes in hairy cell leukemia.
    Ann Hematol. 2020 Nov 20. pii: 10.1007/s00277-020-04349.
    PubMed     Abstract available


  167. ZAPPASODI P, Brociner M, Merati G, Nizzoli ME, et al
    Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Ann Hematol. 2020 Nov 11. pii: 10.1007/s00277-020-04333.
    PubMed    


  168. MORI Y, Sasaki K, Ito Y, Kuriyama T, et al
    Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study.
    Ann Hematol. 2020 Nov 5. pii: 10.1007/s00277-020-04310.
    PubMed     Abstract available


    October 2020
  169. YUAN XL, Tan YM, Shi JM, Zhao YM, et al
    Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2020 Oct 31. pii: 10.1007/s00277-020-04326.
    PubMed     Abstract available


  170. FUJI S, Kida S, Nakata K, Morishima T, et al
    Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Ann Hematol. 2020 Oct 21. pii: 10.1007/s00277-020-04308.
    PubMed     Abstract available


  171. CORNELISSEN LL, Kreuger AL, Caram-Deelder C, Middelburg RA, et al
    Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia - a nested case-control study.
    Ann Hematol. 2020 Oct 17. pii: 10.1007/s00277-020-04298.
    PubMed     Abstract available


  172. PHUKAN A, Mandal PK, Dolai TK
    Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.
    Ann Hematol. 2020 Oct 6. pii: 10.1007/s00277-020-04289.
    PubMed     Abstract available


  173. TAVARES M, Chacim S, Mariz JM
    Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04291.
    PubMed    


  174. MOORE DC, Nelson V, Muslimani A
    Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04285.
    PubMed    


  175. LU Y, Zhao YL, Zhang JP, Xiong M, et al
    Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Ann Hematol. 2020 Oct 1. pii: 10.1007/s00277-020-04283.
    PubMed     Abstract available


  176. JENTZSCH M, Bill M, Grimm J, Brauer D, et al
    Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
    Ann Hematol. 2020;99:2417-2427.
    PubMed     Abstract available


  177. VIARDOT A, Locatelli F, Stieglmaier J, Zaman F, et al
    Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Ann Hematol. 2020;99:2215-2229.
    PubMed     Abstract available


  178. KAWADA K, Ohta T, Fukuda H, Hayashi T, et al
    Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
    Ann Hematol. 2020;99:2429-2436.
    PubMed     Abstract available


  179. BENETATOS L, Benetatou A, Vartholomatos G
    Long non-coding RNAs and MYC association in hematological malignancies.
    Ann Hematol. 2020;99:2231-2242.
    PubMed     Abstract available


  180. ZHANG L, Wang M, Wang Z, Zeng Z, et al
    Identification of a novel ETV6 truncated fusion gene in myeloproliferative neoplasm, unclassifiable with t(4;12)(q12;p13).
    Ann Hematol. 2020;99:2445-2447.
    PubMed    


  181. TEY A, Mohan B, Cheah R, Dendle C, et al
    Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
    Ann Hematol. 2020;99:2455-2456.
    PubMed    


    September 2020
  182. RAMOS-PENAFIEL C, Olarte-Carrillo I, Maldonado RC, de la Cruz Rosas A, et al
    Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia.
    Ann Hematol. 2020 Sep 27. pii: 10.1007/s00277-020-04277.
    PubMed     Abstract available


  183. JING Y, Li YF, Wan H, Liu DH, et al
    Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
    Ann Hematol. 2020 Sep 26. pii: 10.1007/s00277-020-04251.
    PubMed     Abstract available


  184. BALLO O, Kreisel EM, Eladly F, Brunnberg U, et al
    Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy.
    Ann Hematol. 2020 Sep 24. pii: 10.1007/s00277-020-04274.
    PubMed     Abstract available


  185. WEI H, Kuang P, Liu T
    Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
    Ann Hematol. 2020 Sep 22. pii: 10.1007/s00277-020-04258.
    PubMed     Abstract available


  186. ZHAO Y, Rehder C, Wang E
    Circulating blastoid cells: acute leukemia, prolymphocytic leukemia, or something else?
    Ann Hematol. 2020 Sep 15. pii: 10.1007/s00277-020-04270.
    PubMed    


  187. SHI X, Jiang Q, You H, Liu Y, et al
    Rare synchronous co-existence of acute myeloid leukemia and hairy cell leukemia in a same patient.
    Ann Hematol. 2020 Sep 14. pii: 10.1007/s00277-020-04272.
    PubMed    


  188. SHARGIAN-ALON L, Wolach O, Rozovski U, Yahav D, et al
    Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
    Ann Hematol. 2020 Sep 6. pii: 10.1007/s00277-020-04232.
    PubMed     Abstract available


  189. YU J, Ge X, Luo Y, Shi J, et al
    Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia.
    Ann Hematol. 2020 Sep 5. pii: 10.1007/s00277-020-04199.
    PubMed     Abstract available


  190. MINAMIGUCHI H, Fujita H, Atsuta Y, Asou N, et al
    Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia.
    Ann Hematol. 2020 Sep 2. pii: 10.1007/s00277-020-04245.
    PubMed     Abstract available


  191. DUONG VH, Begna KH, Kashanian S, Sweet K, et al
    Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study.
    Ann Hematol. 2020;99:2119-2124.
    PubMed     Abstract available


  192. KOLB HJ, Schmid C
    The FLAMSA concept-past and future.
    Ann Hematol. 2020;99:1979-1988.
    PubMed     Abstract available


  193. VALE CA, Egan PC, Ingham R, Farmakiotis D, et al
    Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
    Ann Hematol. 2020 Sep 1. pii: 10.1007/s00277-020-04238.
    PubMed     Abstract available


    August 2020
  194. ICHIKAWA S, Fujiwara T, Saito K, Fukuhara N, et al
    A novel case of gammadelta T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis.
    Ann Hematol. 2020 Aug 31. pii: 10.1007/s00277-020-04241.
    PubMed    


  195. LIU W, Burger JA, Xu J, Tang Z, et al
    LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Ann Hematol. 2020 Aug 24. pii: 10.1007/s00277-020-04223.
    PubMed     Abstract available


  196. WULLENKORD R, Reicherts C, Mikesch JH, Marx J, et al
    Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Ann Hematol. 2020 Aug 22. pii: 10.1007/s00277-020-04227.
    PubMed    


  197. PEPE S, Scalzulli E, Colafigli G, Di Prima A, et al
    Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Ann Hematol. 2020 Aug 19. pii: 10.1007/s00277-020-04217.
    PubMed     Abstract available


  198. TACHIBANA T, Najima Y, Akahoshi Y, Hirabayashi S, et al
    The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2020 Aug 15. pii: 10.1007/s00277-020-04212.
    PubMed     Abstract available


  199. LE BOURGEOIS A, Labopin M, Marcais A, de Latour RP, et al
    Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFG
    Ann Hematol. 2020;99:1855-1862.
    PubMed     Abstract available


  200. KARA ALI R, Surme S, Balkan II, Salihoglu A, et al
    An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality.
    Ann Hematol. 2020;99:1925-1932.
    PubMed     Abstract available


  201. FLORES V, Miranda R, Merino L, Gonzalez C, et al
    SARS-CoV-2 infection in children with febrile neutropenia.
    Ann Hematol. 2020;99:1941-1942.
    PubMed    


    July 2020
  202. BETTELLI F, Giusti D, Morselli M, Colaci E, et al
    Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study.
    Ann Hematol. 2020 Jul 23. pii: 10.1007/s00277-020-04191.
    PubMed    


  203. SHAHSWAR R, Beutel G, Gabdoulline R, Koenecke C, et al
    Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
    Ann Hematol. 2020 Jul 23. pii: 10.1007/s00277-020-04181.
    PubMed    


  204. MEGIAS-VERICAT JE, Solana-Altabella A, Ballesta-Lopez O, Martinez-Cuadron D, et al
    Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Ann Hematol. 2020 Jul 18. pii: 10.1007/s00277-020-04186.
    PubMed     Abstract available


  205. IKEDA Y, Yamanouchi J, Takenaka K
    Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
    Ann Hematol. 2020 Jul 16. pii: 10.1007/s00277-020-04185.
    PubMed    


  206. CHENG FM, Tien JZ, Chen TT, Yeh SP, et al
    Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04168.
    PubMed    


  207. ZANELLI M, Ricci S, Zizzo M, Sanguedolce F, et al
    Bone marrow coexistence of chronic lymphocytic leukemia and Langerhans cell sarcoma.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04167.
    PubMed    


  208. KUNADT D, Dransfeld C, Dill C, Schmiedgen M, et al
    Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia.
    Ann Hematol. 2020 Jul 3. pii: 10.1007/s00277-020-04163.
    PubMed     Abstract available


  209. CHENG Z, Luo Y, Zhang Y, Wang Y, et al
    A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction.
    Ann Hematol. 2020;99:1561-1564.
    PubMed     Abstract available


  210. KOVAL SV, Gluzman DF, Sklyarenko LM, Ivanivska TS, et al
    Hematological malignancies in Ukraine in post-Chernobyl era: sources of data and their preliminary analysis.
    Ann Hematol. 2020;99:1543-1550.
    PubMed     Abstract available


    June 2020
  211. HINZE A, Rinke J, Hochhaus A, Ernst T, et al
    Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
    Ann Hematol. 2020 Jun 23. pii: 10.1007/s00277-020-04152.
    PubMed    


  212. LI Z, Lai Y, Zhang X, Xu L, et al
    Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2020 Jun 23. pii: 10.1007/s00277-020-04155.
    PubMed     Abstract available


  213. MARTINS F, Kruszewski M, Scarpelli I, Schoumans J, et al
    Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04114.
    PubMed     Abstract available


  214. HOCHMAN MJ, Martin DB
    Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04091.
    PubMed    


  215. ROBAK P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, et al
    Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment.
    Ann Hematol. 2020 Jun 12. pii: 10.1007/s00277-020-04121.
    PubMed    


  216. STEMLER J, Koehler P, Maurer C, Muller C, et al
    Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
    Ann Hematol. 2020 Jun 8. pii: 10.1007/s00277-020-04107.
    PubMed     Abstract available


  217. YANAGISAWA H, Mizuta S, Kawabata H, Fujimoto S, et al
    Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion.
    Ann Hematol. 2020 Jun 8. pii: 10.1007/s00277-020-04122.
    PubMed    


  218. BECKER H, Pfeifer D, Ihorst G, Pantic M, et al
    Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Ann Hematol. 2020 Jun 6. pii: 10.1007/s00277-020-04082.
    PubMed     Abstract available


  219. ARCHIBALD WJ, Rabe KG, Kabat BF, Herrmann J, et al
    Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Ann Hematol. 2020 Jun 1. pii: 10.1007/s00277-020-04094.
    PubMed     Abstract available


    May 2020
  220. MULAS O, Caocci G, Stagno F, Bonifacio M, et al
    Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
    Ann Hematol. 2020 May 30. pii: 10.1007/s00277-020-04102.
    PubMed     Abstract available


  221. SCALZULLI E, Colafigli G, Latagliata R, Pepe S, et al
    Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
    Ann Hematol. 2020 May 28. pii: 10.1007/s00277-020-04096.
    PubMed     Abstract available


  222. CHEN Q, Zhao X, Fu HX, Chen YH, et al
    Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia.
    Ann Hematol. 2020 May 26. pii: 10.1007/s00277-020-04080.
    PubMed     Abstract available


  223. MAAKARON JE, Ozga MP, Mannis GN, Pulley W, et al
    Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
    Ann Hematol. 2020 May 6. pii: 10.1007/s00277-020-04054.
    PubMed    


  224. YANADA M, Takami A, Yamasaki S, Arai Y, et al
    Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.
    Ann Hematol. 2020 May 4. pii: 10.1007/s00277-020-04051.
    PubMed     Abstract available


    April 2020
  225. HELBIG G, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, et al
    Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
    Ann Hematol. 2020 Apr 24. pii: 10.1007/s00277-020-04026.
    PubMed     Abstract available


  226. HORISAWA Y, Kondo T, Hishizawa M, Yamashita K, et al
    A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
    Ann Hematol. 2020 Apr 21. pii: 10.1007/s00277-020-04029.
    PubMed    


  227. BRUMMENDORF TH, Gambacorti-Passerini C, Bushmakin AG, Cappelleri JC, et al
    Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04018.
    PubMed     Abstract available


  228. GAO M, Zhao X
    Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Ann Hematol. 2020 Apr 19. pii: 10.1007/s00277-020-04037.
    PubMed    


  229. GUPTA C, Kaulfuss S, Gorlich K, Othman B, et al
    Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
    Ann Hematol. 2020 Apr 15. pii: 10.1007/s00277-020-04001.
    PubMed    


  230. MIN GJ, Cho BS, Park SS, Park S, et al
    Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Ann Hematol. 2020 Apr 8. pii: 10.1007/s00277-020-04010.
    PubMed     Abstract available


  231. SPIESS B, Kleiner H, Flach J, Fabarius A, et al
    Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients.
    Ann Hematol. 2020 Apr 6. pii: 10.1007/s00277-020-04007.
    PubMed     Abstract available


  232. APEL A, Ofran Y, Wolach O, Shimony S, et al
    Safety and efficacy of blinatumomab: a real world data.
    Ann Hematol. 2020;99:835-838.
    PubMed     Abstract available


  233. BUSSAGLIA E, Pratcorona M, Carricondo M, Sansegundo L, et al
    Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies).
    Ann Hematol. 2020;99:765-772.
    PubMed     Abstract available


    March 2020
  234. OZBAGCIVAN O, Akarsu S, Nazli EC, Lebe B, et al
    Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 27. pii: 10.1007/s00277-020-04009.
    PubMed    


    February 2020
  235. GRUHN B, Brodt G, Wittig S, Ernst T, et al
    Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL.
    Ann Hematol. 2020 Feb 18. pii: 10.1007/s00277-020-03957.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: